Submit manuscript...
Journal of
eISSN: 2376-0060

Lung, Pulmonary & Respiratory Research

Editorial Volume 9 Issue 3

Whole inactivated COVID-19 vaccines: effect on adult symptomatic-COVID-19 infection

Attapon Cheepsattayakorn,1,2 Ruangrong Cheepsattayakorn,3 Porntep Siriwanarangsun1

1Faculty of Medicine, Western University, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Thailand
3Department of Pathology, Chiang Mai University, Thailand

Correspondence: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand

Received: September 10, 2022 | Published: September 14, 2022

Citation: Cheepsattayakorn A, Cheepsattayakorn R, Siriwanarangsun P. Whole inactivated COVID-19 vaccines: effect on adult symptomatic-COVID-19 infection. J Lung Pulm Respir Res. 2022;9(3):61. DOI: 10.15406/jlprr.2022.09.00281

Download PDF

Editorial

Recently, a large phase-III-clinical trial on persons with age of 18 years or above, conducted by Bharat Biotech International Limited, “ COVAXIN® ” (BBV152), a whole vision inactivated corona virus vaccine demonstrated that two doses of its vaccine with an interval of 4 weeks of administration had 78 % of efficacy against any COVID-19 (live SARS-CoV-2) severity and 93 % of efficacy against severe COVID-19 after 14 days or more after the second dose administration.1 Whereas vaccine efficacy was 79 % in adults with age of 60 years or below, and 68 % in those with age of 60 years or above.1 On the median of follow-up of 99 days, the vaccine efficacy in persons with asymptomatic COVID-19 infection was 64 %.1 A recent study on effect of two whole inactivated COVID-19 vaccines (two intramuscular injections, 21 days apart) among adults with symptomatic COVID-19 infection revealed that COVID-19 vaccine with 5 µg/dose (n = 13,459) and vaccine with 4 µg/dose (n = 13,465) had the vaccine efficacy of 72.8 % and 78.1 %, respectively, compared with control group (n = 13,458) of 95 % (77 days of median duration), whereas the adverse reactions at 7 days after each injection were around 41.7 % to 46.5 % of the study participants.2

In conclusion, these two whole inactivated COVID-19 vaccines could decrease the risk of symptomatic COVID-19 infection among adults, whereas the use of COVAXIN® in adults with age of 18 years or above.

Acknowledgments

None.

Conflicts of interest

There are no conflicting interests declared by the authors.

References

Creative Commons Attribution License

©2022 Cheepsattayakorn, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.